Logo image of CRNX

CRINETICS PHARMACEUTICALS IN (CRNX) Stock Fundamental Analysis

USA - NASDAQ:CRNX - US22663K1079 - Common Stock

42.49 USD
+0.92 (+2.21%)
Last: 10/20/2025, 2:51:06 PM
Fundamental Rating

3

Taking everything into account, CRNX scores 3 out of 10 in our fundamental rating. CRNX was compared to 191 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for CRNX as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, CRNX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CRNX has reported negative net income.
CRNX had a negative operating cash flow in the past year.
CRNX had negative earnings in each of the past 5 years.
In the past 5 years CRNX always reported negative operating cash flow.
CRNX Yearly Net Income VS EBIT VS OCF VS FCFCRNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

Looking at the Return On Assets, with a value of -28.68%, CRNX is in line with its industry, outperforming 52.88% of the companies in the same industry.
CRNX has a Return On Equity (-31.57%) which is in line with its industry peers.
Industry RankSector Rank
ROA -28.68%
ROE -31.57%
ROIC N/A
ROA(3y)-33.7%
ROA(5y)-34.4%
ROE(3y)-38.05%
ROE(5y)-38.05%
ROIC(3y)N/A
ROIC(5y)N/A
CRNX Yearly ROA, ROE, ROICCRNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

CRNX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRNX Yearly Profit, Operating, Gross MarginsCRNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K -80K -100K

More info and screens

8

2. Health

2.1 Basic Checks

CRNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
CRNX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CRNX has more shares outstanding
CRNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CRNX Yearly Shares OutstandingCRNX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CRNX Yearly Total Debt VS Total AssetsCRNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

2.2 Solvency

An Altman-Z score of 18.62 indicates that CRNX is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 18.62, CRNX belongs to the best of the industry, outperforming 90.58% of the companies in the same industry.
There is no outstanding debt for CRNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 18.62
ROIC/WACCN/A
WACC8.73%
CRNX Yearly LT Debt VS Equity VS FCFCRNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

CRNX has a Current Ratio of 17.80. This indicates that CRNX is financially healthy and has no problem in meeting its short term obligations.
CRNX has a Current ratio of 17.80. This is amongst the best in the industry. CRNX outperforms 87.96% of its industry peers.
CRNX has a Quick Ratio of 17.80. This indicates that CRNX is financially healthy and has no problem in meeting its short term obligations.
CRNX has a better Quick ratio (17.80) than 87.96% of its industry peers.
Industry RankSector Rank
Current Ratio 17.8
Quick Ratio 17.8
CRNX Yearly Current Assets VS Current LiabilitesCRNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

4

3. Growth

3.1 Past

CRNX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.73%.
CRNX shows a small growth in Revenue. In the last year, the Revenue has grown by 0.22%.
Measured over the past years, CRNX shows a decrease in Revenue. The Revenue has been decreasing by -2.68% on average per year.
EPS 1Y (TTM)-8.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-30.85%
Revenue 1Y (TTM)0.22%
Revenue growth 3Y-1.28%
Revenue growth 5Y-2.68%
Sales Q2Q%158.4%

3.2 Future

The Earnings Per Share is expected to grow by 22.14% on average over the next years. This is a very strong growth
CRNX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 266.90% yearly.
EPS Next Y-30.67%
EPS Next 2Y-17.24%
EPS Next 3Y-0.1%
EPS Next 5Y22.14%
Revenue Next Year227.08%
Revenue Next 2Y488.29%
Revenue Next 3Y373.41%
Revenue Next 5Y266.9%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CRNX Yearly Revenue VS EstimatesCRNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B
CRNX Yearly EPS VS EstimatesCRNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10 15 20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CRNX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRNX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRNX Price Earnings VS Forward Price EarningsCRNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRNX Per share dataCRNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.24%
EPS Next 3Y-0.1%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CRNX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CRINETICS PHARMACEUTICALS IN

NASDAQ:CRNX (10/20/2025, 2:51:06 PM)

42.49

+0.92 (+2.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-06 2025-11-06/amc
Inst Owners113.2%
Inst Owner Change0.2%
Ins Owners1.75%
Ins Owner Change-5.27%
Market Cap4.00B
Analysts83.48
Price Target81.09 (90.84%)
Short Float %16.18%
Short Ratio11.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-9.07%
Min EPS beat(2)-9.79%
Max EPS beat(2)-8.34%
EPS beat(4)1
Avg EPS beat(4)-4.63%
Min EPS beat(4)-9.79%
Max EPS beat(4)2.94%
EPS beat(8)1
Avg EPS beat(8)-7.01%
EPS beat(12)2
Avg EPS beat(12)-4.86%
EPS beat(16)3
Avg EPS beat(16)-6.43%
Revenue beat(2)2
Avg Revenue beat(2)485.92%
Min Revenue beat(2)289.31%
Max Revenue beat(2)682.52%
Revenue beat(4)2
Avg Revenue beat(4)192.96%
Min Revenue beat(4)-100%
Max Revenue beat(4)682.52%
Revenue beat(8)4
Avg Revenue beat(8)121.09%
Revenue beat(12)8
Avg Revenue beat(12)171.08%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)11.63%
PT rev (3m)7.33%
EPS NQ rev (1m)-1.5%
EPS NQ rev (3m)-7.17%
EPS NY rev (1m)0.07%
EPS NY rev (3m)-5.83%
Revenue NQ rev (1m)-39.92%
Revenue NQ rev (3m)-9.92%
Revenue NY rev (1m)-7.15%
Revenue NY rev (3m)5.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2874.79
P/FCF N/A
P/OCF N/A
P/B 3.42
P/tB 3.42
EV/EBITDA N/A
EPS(TTM)-4.11
EYN/A
EPS(NY)-5.1
Fwd EYN/A
FCF(TTM)-3.27
FCFYN/A
OCF(TTM)-3.2
OCFYN/A
SpS0.01
BVpS12.44
TBVpS12.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.68%
ROE -31.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.7%
ROA(5y)-34.4%
ROE(3y)-38.05%
ROE(5y)-38.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 174.26%
Cap/Sales 430.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.8
Quick Ratio 17.8
Altman-Z 18.62
F-Score3
WACC8.73%
ROIC/WACCN/A
Cap/Depr(3y)244.79%
Cap/Depr(5y)160.44%
Cap/Sales(3y)173.94%
Cap/Sales(5y)166.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-30.85%
EPS Next Y-30.67%
EPS Next 2Y-17.24%
EPS Next 3Y-0.1%
EPS Next 5Y22.14%
Revenue 1Y (TTM)0.22%
Revenue growth 3Y-1.28%
Revenue growth 5Y-2.68%
Sales Q2Q%158.4%
Revenue Next Year227.08%
Revenue Next 2Y488.29%
Revenue Next 3Y373.41%
Revenue Next 5Y266.9%
EBIT growth 1Y-52.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-40.75%
EBIT Next 3Y-3.63%
EBIT Next 5YN/A
FCF growth 1Y-90.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-88.46%
OCF growth 3YN/A
OCF growth 5YN/A